Biomab EGFR 50 mg Injection
676,90$
527,99$
Biomab EGFR 50 mg Injection is a humanized monoclonal antibody designed to target the epidermal growth factor receptor (EGFR), playing a crucial role in the management of various cancers. This innovative treatment option is indicated for patients suffering from head and neck cancers, colorectal cancer, as well as specific brain tumors such as glioma and glioblastoma. Biomab EGFR can be utilized as a standalone therapy or in conjunction with chemotherapy and radiotherapy to enhance overall efficacy. By inhibiting EGFR, Biomab EGFR helps slow down tumor growth and progression, offering hope to those facing these challenging diagnoses. It is important for patients to discuss potential side effects and contraindications with their healthcare provider before starting this medication, as individual responses may vary. Biomab EGFR is a pivotal addition to the oncology landscape, providing targeted treatment that aligns with modern cancer care practices. For optimal results, adherence to prescribed treatment regimens and regular monitoring by a healthcare professional are essential. This injection represents a significant advancement in personalized medicine, focusing on improving outcomes for patients battling aggressive forms of cancer.
Cantidad
Active Pharmaceutical Ingredient
Uses
• Biomab egfr 50 mg injection is primarily used in the treatment of head and neck cancers. It targets specific receptors that are often overexpressed in these tumors, helping to inhibit their growth. By blocking these receptors, Biomab egfr 50 mg injection can enhance the effectiveness of other therapies. This makes it a valuable option for patients with advanced disease.
• Another significant application of Biomab egfr 50 mg injection is in managing colorectal cancer. This medication is designed to interfere with cancer cell proliferation by targeting the epidermal growth factor receptor (EGFR). When used in conjunction with chemotherapy, Biomab egfr 50 mg injection can improve outcomes for patients with metastatic or locally advanced colorectal cancer. Its use is particularly beneficial in cases where traditional treatments may not be sufficient.
• Biomab egfr 50 mg injection is also indicated for the treatment of glioblastoma, a type of aggressive brain tumor. This injection works by disrupting the signaling pathways that promote tumor growth and survival. In patients with recurrent glioblastoma, Biomab egfr 50 mg injection can provide a new avenue for therapy, potentially extending survival. Its targeted action offers hope in a challenging treatment landscape.
• In addition to its primary uses, Biomab egfr 50 mg injection may be explored in various clinical settings for other cancers that exhibit EGFR overexpression. Research is ongoing to evaluate its efficacy in different malignancies. Healthcare providers consider Biomab egfr 50 mg injection a critical component in personalized cancer treatment plans. Its versatility and targeted approach continue to be subjects of interest in oncology.
Benefits
Head and neck cancer: Head and neck cancer includes cancers of the mouth, nose, sinuses or throat. Biomab EGFR Injection kills or stops the growth of cancer cells and also prevents cancer cells from multiplying. It is a strong and very toxic medicine, and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol or smoking during this treatment and drink plenty of water to stay hydrated. Cancer of the colon and rectum: Cancer of the colon and rectum, also known as colorectal cancer (CRC) or bowel cancer, is the development of cancer in two parts of the large intestine, the colon or rectum. With this type of cancer, a person may notice symptoms such as blood in the stool, a change in bowel movements, weight loss and fatigue. Biomab EGFR 50 Injection treats and also reduces the risk of developing other cancerous growths (polyps) and bowel cancer. It kills or stops the growth of cancer cells and also stops cancer cells from multiplying. It is an effective medicine, but it does have some side effects. Talk to your physician when you have any concerns. Glioblastoma (cancer of the brain and spinal cord) Glioblastoma is a type of cancer that starts as a growth of cells in the brain or spinal cord. It works by targeting the epidermal growth factor receptor (EGFR), which is often found in high levels on the surface of glioblastoma cells. By binding to EGFR, Biomab EGFR 50 mg can interfere with the growth and spread of these cancer cells.
Side Effects
Like all medicines, Biomab EGFR 50 mg Injection may cause side effects which do not require medical attention and which will disappear as your body adjusts to the medicine. Tell your doctor if they persist or if you're worried about them.
Most Common Side Effects
• Fever
• Rashes
• Itching
• Nausea
• Vomiting
• Chills
• Rigors
• Altered liver enzymes
Common Side Effects
• Drowsiness
• Disorientation
• Changes in blood pressure like hypotension or hypertension
• Hematuria ( Blood in urine)
• Weakness
• Allergic reaction
• Fatigue
• Diarrhoea
• Dizziness
How To Use
Biomab EGFR 50 mg Injection is used as an IV (intravenous) infusion to be given intravenously into a vein under the supervision of a healthcare professional. This medicine must be given slowly as advised by your doctor. Don't give yourself medicine at home without medical supervision.
Safety Advice
• Alcohol: Drinking alcohol while taking Biomab EGFR 50 mg is generally not recommended. It may increase the risk of liver damage and it is best to avoid alcohol or to limit the amount of alcohol you drink while you are taking this medicine.
• Kidney: In patients with kidney disease, Biomab EGFR 50 mg Injection should be used with caution and kidney function should be closely monitored. If you experience any side effects or you have concerns about using this Biomab EGFR 50 Injection, please consult your doctor.
• Breastfeeding: There are no data on the presence of Biomab EGFR 50 mg or its metabolites in human milk or effects on nursing infants or lactation. Because of the potential for serious adverse reactions in nursing infants, women should be advised not to breastfeed during treatment with Biomab EGFR 50 Injection and for 2 weeks after the last dose.
• Liver: In patients with liver disease, Biomab EGFR Injection should be used with caution, and liver function should be closely monitored. If you experience any side effects or have concerns about using this Biomab EGFR 50 Injection, please consult your doctor.
• Pregnancy: The use of Biomab EGFR 50 mg Injection is not recommended in pregnant women as it may cause harm to the foetus if administered to a pregnant woman.
• Driving: Biomab EGFR 50 mg Injection may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Biomab EGFR 50 mg.